Does patent status for pravastatin affect its price compared with Lipitor?
Pravastatin is off-patent and is widely available as low-cost generics, so its market price is mainly driven by generic competition rather than exclusivity or ongoing patent protection. That generally keeps pravastatin cheaper than newer, still-extended products like brand-name Lipitor.
Lipitor (atorvastatin) also went off patent years ago and is available as generic, which means the strongest “patent vs. no patent” cost difference shows up mostly when comparing brand pricing (where exclusivity can still matter) versus generic pricing (where it does not). If you are comparing both drugs as generics, patent status is usually not the main cost driver because both products compete in the generic market.
What happens to cost once a statin goes generic?
When patent protections end, multiple generic manufacturers can enter, increasing supply and compressing prices. For pravastatin, the availability of many generic versions typically reduces cost for patients and payers. For Lipitor, once generic versions were available, its cost also fell substantially relative to brand-only pricing.
How to tell whether you’re seeing “patent impact” or “generic competition” in your bill
The size of the price gap often depends on what you’re actually purchasing:
- Brand-name (non-generic) versus generic: Brand pricing is more likely to reflect any remaining exclusivity rules.
- Generic versus generic: Costs tend to be similar across statins in the same tier and are shaped more by negotiated pharmacy pricing, insurance formularies, and dose than by patent status.
- Specialty pharmacy vs retail: Contract pricing can make one generic cheaper than another even if patent timelines are irrelevant.
Does switching from brand Lipitor to generic atorvastatin change the relevance of patents?
Yes. Once you use generic atorvastatin, patent status is much less relevant because the competing generics drive pricing. At that point, the main differences between pravastatin and Lipitor are usually potency, dosing convenience, and insurance coverage, not exclusivity.
Bottom line
Patent status can influence costs mainly when one drug is still sold as a brand under exclusivity while the other is already generic. For pravastatin versus Lipitor, the typical real-world cost difference is more consistent with generic availability and competitive pricing than with ongoing patent effects—especially if both are being filled as generics.